Clinical Trial Update: A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study update for F520 in locally advanced or metastatic urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• F520

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma | Phase 2 | Status: UNKNOWN